Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance
Norma Bloy, Pauline Garcia, Céline M. Laumont, et al.
Immunological Reviews (2017) Vol. 280, Iss. 1, pp. 165-174
Closed Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Rong Tang, Jin Xu, Bo Zhang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 980
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi, Ilio Vitale, Sarah H. Warren, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000337-e000337
Open Access | Times Cited: 857
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Razan Alzeibak, Tatiana A. Mishchenko, Natalia Y. Shilyagina, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 1, pp. e001926-e001926
Open Access | Times Cited: 407
Metal Drugs and the Anticancer Immune Response
Bernhard Englinger, Christine Pirker, Petra Heffeter, et al.
Chemical Reviews (2018) Vol. 119, Iss. 2, pp. 1519-1624
Open Access | Times Cited: 307
Polyploidy in liver development, homeostasis and disease
Romain Donné, Maëva Saroul-Aïnama, Pierre Cordier, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 7, pp. 391-405
Closed Access | Times Cited: 154
Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications
Nem Singh, Jungryun Kim, Jaewon Kim, et al.
Bioactive Materials (2022) Vol. 21, pp. 358-380
Open Access | Times Cited: 84
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Kyu-Won Lee, Judy Wai Ping Yam, Xiaowen Mao
Cells (2023) Vol. 12, Iss. 17, pp. 2147-2147
Open Access | Times Cited: 51
Nanoplatform-enhanced photodynamic therapy for the induction of immunogenic cell death
Xu Liu, Yichao Lu, Xiang Li, et al.
Journal of Controlled Release (2024) Vol. 365, pp. 1058-1073
Closed Access | Times Cited: 28
Nanomedicines for an Enhanced Immunogenic Cell Death-Based In Situ Cancer Vaccination Response
Caiyan Zhao, Changrong Wang, Wenbo Shan, et al.
Accounts of Chemical Research (2024) Vol. 57, Iss. 6, pp. 905-918
Closed Access | Times Cited: 25
Trial watch: Peptide-based vaccines in anticancer therapy
Lucillia Bezu, Oliver Kepp, Giulia Cerrato, et al.
OncoImmunology (2018) Vol. 7, Iss. 12, pp. e1511506-e1511506
Open Access | Times Cited: 144
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Oliver Kepp, Aurélien Marabelle, Laurence Zitvogel, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 1, pp. 49-64
Closed Access | Times Cited: 126
Immune Landscape of Breast Cancers
Divya Nagarajan, Stéphanie McArdle
Biomedicines (2018) Vol. 6, Iss. 1, pp. 20-20
Open Access | Times Cited: 111
Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation
Annamaria Gullà, Eugenio Morelli, Mehmet Samur, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 5, pp. 468-483
Open Access | Times Cited: 102
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
Lucia D’Amico, Ulrike Menzel, Michael Prummer, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 95
Autophagy and Energy Metabolism
Jie Yang, Ruimin Zhou, Zhenyi Ma
Advances in experimental medicine and biology (2019), pp. 329-357
Closed Access | Times Cited: 89
Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening
Antonella Sistigu, Martina Musella, Claudia Galassi, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 83
Beneficial autoimmunity improves cancer prognosis
Laurence Zitvogel, Claude Perreault, Olivera J. Finn, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 591-602
Open Access | Times Cited: 82
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
Hui‐Ching Wang, Leong‐Perng Chan, Shih‐Feng Cho
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 79
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
María Julia Lamberti, Annunziata Nigro, Fátima María Mentucci, et al.
Pharmaceutics (2020) Vol. 12, Iss. 3, pp. 256-256
Open Access | Times Cited: 77
AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
Maria L. Lotsberg, Katarzyna Wnuk-Lipińska, Stéphane Terry, et al.
Journal of Thoracic Oncology (2020) Vol. 15, Iss. 6, pp. 973-999
Open Access | Times Cited: 76
Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress
Juliette Humeau, Allan Sauvat, Giulia Cerrato, et al.
EMBO Molecular Medicine (2020) Vol. 12, Iss. 5
Open Access | Times Cited: 72
Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival
Rania F. Zaarour, Bilal Azakir, Edries Yousaf Hajam, et al.
Cancers (2021) Vol. 13, Iss. 3, pp. 533-533
Open Access | Times Cited: 71
Polymeric nanoparticle-based nanovaccines for cancer immunotherapy
Yongxin Zhang, Jiajing Chen, Linqi Shi, et al.
Materials Horizons (2022) Vol. 10, Iss. 2, pp. 361-392
Closed Access | Times Cited: 52
Extracellular vesicles as next generation immunotherapeutics
David W. Greening, Rong Xu, Anukreity Ale, et al.
Seminars in Cancer Biology (2023) Vol. 90, pp. 73-100
Closed Access | Times Cited: 41
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Mustafa Özgüroğlu, Saadettin Kılıçkap, Ahmet Sezer, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 9, pp. 989-1001
Closed Access | Times Cited: 35
Page 1 - Next Page

Scroll to top